- Russia’s Sputnik V vaccine 92% effective in fighting COVID-19 (reuters.com)
Scientists gave Russia’s Sputnik V vaccine the green light...saying it was almost 92% effective in fighting COVID-19 based on peer-reviewed late-stage trial results published in The Lancet international medical journal...The results, collated by the Gamaleya Institute in Moscow that developed and tested the vaccine, were in line with efficacy data reported at earlier stages of the trial, which has been running in Moscow since September...READ MORE
- Trying to stay ahead of SARS-CoV-2 as variants emerge (bioworld.com)New COVID-19 variants challenging vaccine makers amid rollout (bioworld.com)
A new national consortium of virologists has been set up to systematically assess how mutations in SARS-CoV-2 affect key outcomes such as effectiveness of vaccines and therapies, transmissibility of the virus and the severity of COVID-19 infections...Now is the critical time to do this, as the level of both natural and vaccine-conferred immunity that might drive natural selection is increasing, said Wendy Barclay, head of the department of infectious disease at Imperial College London, who is leading the G2P-UK (Genotype to Phenotype-UK) project...“The virus has circulated in humans for more than a year; we’re in a phase where the virus is constantly throwing up new variants and we need to gear up to assess the risk they pose, and to understand the mechanisms by which they act,” Barclay said...READ MORE
- Report: 2010 Government Vaccine Dollars Misused on Unrelated Expenses (biospace.com)
A special fund for vaccine research that was set aside by the U.S. Department of Health and Human Services in 2010 has been misused to pay for unrelated expenses, a government report shows...In a letter to newly-inaugurated President Joe Biden and Congress, the U.S. Office of Special Counsel said millions of dollars intended to be used to bolster preparedness for public health emergencies such as the ongoing COVID-19 pandemic and other potential viral outbreaks, have been flagrantly misused to finance other expenses...READ MORE
- Forbes: Dr. Anthony Fauci: The Highest Paid Employee In The Entire U.S. Federal Government (openthebooks.com)
Dr. Anthony Fauci made $417,608 in 2019, the latest year for which federal salaries are available. That made him not only the highest paid doctor in the federal government, but the highest paid out of all four million federal employees...In fact, Dr. Fauci even made more than the $400,000 salary of the President of the United States. All salary data was collected by OpenTheBooks.com via Freedom of Information Act requests...In an August 13, 2020 Instagram interview with actor Matthew McConaughey, Dr. Fauci was asked if he had millions of dollars invested in the vaccines. Dr. Fauci laughed and answered, “Matthew, no, I got zero! I am a government worker. I have a government salary.”...READ MORE
- Analysis: Nevada getting shortchanged in vaccine dose allocation (reviewjournal.com)
Nevada health officials are sending a message to federal agencies allocating COVID-19 vaccines to states: Show us your math...Questions have dogged state officials since Centers for Disease Control and Prevention data showed Nevada consistently ranking near the bottom of national lists for both receiving vaccine doses and putting shots into arms...Each state’s vaccine allocation is purportedly proportional to its adult population, but officials have offered conflicting information on what year’s population numbers are being used...READ MORE
- Order up: U.S. calls on Pfizer, Moderna for 200M more vaccine doses (fiercepharma.com)Biden Administration Announces Steps to Ramp Up COVID-19 Vaccine Rollout (drugtopics.com)
Pfizer and Moderna have agreed to deliver another 200 million COVID-19 vaccine doses to the U.S., bringing the total on tap to 600 million, or enough to vaccinate 300 million people...President Joe Biden announced the pending deals on Tuesday, noting the extra doses would be delivered this summer. Moderna confirmed the negotiations in a press release...although it said the discussions are for “delivery in the third quarter of 2021.” Pfizer also confirmed the negotiations but didn't specify the timing...READ MORE
- Moderna Developing Booster COVID-19 Shot to Quell Tide of New Variants (biospace.com)
Moderna announced it has started development on a booster to its COVID-19 vaccine, which the company hopes will work against the recently discovered (and more transmissible) SARS-CoV-2 variant from South Africa...Moderna’s COVID-19 vaccine mRNA-1273 appears to be effective for protecting against B.1.1.7 and B.1.351, two highly infectious strains first discovered in the U.K. and South Africa, respectively...The South African B.1.351 variant features ten mutations found in the spike protein of SARS-CoV-2, the novel coronavirus responsible for COVID-19. Variants from both the U.K. and South Africa have spread quickly across the globe, with some data suggesting these variants are associated with increased transmission and greater post-infection viral burden...READ MORE
- mRNA Vaccines Prove Their Worth Against COVID-19 Variants (biospace.com)Data From COVID-19 Vaccine Makers Demonstrate Immunity Against SARS-CoV-2 Variants (pharmacypracticenews.com)
The data is continuing to come in on the various COVID-19 variants, and so far the news is pretty good. Pfizer and BioNTech announced that their COVID-19 vaccine appears effective against an engineered virus developed with three key mutations found in the South African variant. This was conducted in a laboratory test by Pfizer and the University of Texas Medical Branch...the data has not yet been peer-reviewed, it demonstrated a less than two-fold decrease in antibody titer levels. The bottom line is that the Pfizer-BioNTech vaccine is likely effective in neutralizing the E484K and N501Y mutations found in the South African variant...READ MORE
- AstraZeneca, EU officials duke it out in the press as COVID-19 vaccine supply battle heats up (fiercepharma.com)
Within days of AstraZeneca's surprise cut to first-quarter COVID-19 vaccine deliveries to Europe, a fierce debate between the drugmaker and government officials is playing out behind the scenes—and in the press...CEO Pascal Soriot said the company has no legal obligation to deliver vaccines on a specific timeline. The EU maintains AZ’s new delivery schedule is “not acceptable.”...The sides were set to meet Wednesday, but an EU official told Politico the drugmaker had pulled out. AstraZeneca told Fierce Pharma via email it hadn't...READ MORE
- Merck Ends Covid-19 Vaccine Program, Shifts Focus to Therapeutics (biospace.com)
Merck announced that it is going to stop developing its two COVID-19 vaccine candidates, dubbed V590 and V591, after poor responses in Phase I trials. They are shifting their attention to advancing two therapeutic drugs for COVID-19, MK-4482 and MK-7110...“We are grateful to our collaborators who worked with us on these vaccine candidates and to the volunteers in the trials,” said Dean Y. Li, president, Merck Research Laboratories. “We are resolute in our commitment to contribute to the global effort to relieve the burden of this pandemic on patients, health care systems and communities.”...READ MORE